Ambien Hits Back at Roseanne: “Racism Is Not a Known Side Effect”

The just-fired TV host had blamed her sleeping pills for a bigoted tweet.

Kristin Callahan/ZUMA

Fight disinformation. Get a daily recap of the facts that matter. Sign up for the free Mother Jones newsletter.

The manufacturer of Ambien is pushing back against Roseanne Barr’s attempt to blame the drug for a racist tweet she published and deleted Tuesday. 

“People of all races, religions and nationalities work at Sanofi every day to improve the lives of people around the world,” Sanofi US, the company behind the commonly prescribed sleeping pill, said in a Wednesday statement. “While all pharmaceutical treatments have side effects, racism is not a known side effect of any Sanofi medication.”

The company was responding to another since deleted tweet Barr sent on Wednesday, where the TV star claimed “ambien tweeting” prompted her to liken Valerie Jarrett, a former senior adviser to Barack Obama who is black, to an ape. Just hours after that tweet gained attention on social media, ABC said it was canceling Roseanne for what it denounced as an “abhorrent” and “repugnant” statement by Barr.

The 2018 reboot of the popular sitcom had been attracting high ratings—even while some jokes drew controversy and as Barr kept up her well-established record of promoting baseless, right-wing conspiracy theories.

Despite Barr’s announcement that she would soon be leaving Twitter, along with a public apology she sent to Jarrett, Barr continued to retweet right-wing conspiracy theories about the former Obama adviser well into Wednesday evening. Other Barr retweets suggested ABC was wrong to cancel Roseanne and that Barr thought the company had applied a double standard in choosing to dismiss her.

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you'll agree is worth supporting.

payment methods

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you’ll agree is worth supporting.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate